BRAF and melanoma: Hence, we analyzed CRISPR screens in Fig. 5A using conventional FC or v as metrics of viability in the presence and absence of the BRAF inhibitor, vemurafenib [42], to identify genes whose ablation could sensitize melanoma cells to vemurafenib.